Previous 10 |
home / stock / cerew / cerew news
BOSTON, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside c...
Participants dosed in clinical trials for lead programs in schizophrenia, epilepsy, anxiety and Parkinson’s disease Debuted as publicly traded entity under symbol CERE Net proceeds of approximately $440 million raised from completed business combination transa...
BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that members of the management team will participate in three upcoming virtual investor con...
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the first participants have been dosed in all three of the clinical trials in th...
News, Short Squeeze, Breakout and More Instantly...
Cerevel Therapeutics Holdings Inc. Warrant Company Name:
CEREW Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that chairperson and chief executive officer Tony Coles, M.D. will participate in...
On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now expected mid-year 2023, revised from 2H 2022 $550.9M in cash, cash equivalents...
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2022 financial results on Tuesday, May 10, 2...